Cargando…

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

BACKGROUND: Innovative coronavirus disease 2019 (COVID-19) vaccines, with elevated global manufacturing capacity, enhanced safety and efficacy, simplified dosing regimens, and distribution that is less cold chain-dependent, are still global imperatives for tackling the ongoing pandemic. A previous p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Ya-Jun, He, Jian-Feng, Pei, Rong-Juan, He, Peng, Huang, Zhu-Hang, Chen, Shao-Min, Ou, Zhi-Qiang, Deng, Jing-Long, Zeng, Pei-Yu, Zhou, Jian, Min, Yuan-Qin, Deng, Fei, Peng, Hua, Zhang, Zheng, Wang, Bo, Xu, Zhong-Hui, Guan, Wu-Xiang, Hu, Zhong-Yu, Zhang, Ji-Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382383/ https://www.ncbi.nlm.nih.gov/pubmed/34310400 http://dx.doi.org/10.1097/CM9.0000000000001702

Ejemplares similares

Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial
por: Zhang, Jikai, et al.
Publicado: (2021)

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
por: Wang, Xuan-Yi, et al.
Publicado: (2022)

Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial
por: Wang, Guiqiang, et al.
Publicado: (2022)

Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial
por: Yao, Dan-Ni, et al.
Publicado: (2016)

Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials
por: Meng, Fan-Yue, et al.
Publicado: (2021)

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
por: Richmond, Peter, et al.
Publicado: (2021)

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
por: Zhu, Feng-Cai, et al.
Publicado: (2020)

Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus
por: Zhang, Heng, et al.
Publicado: (2022)

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
por: Yang, Shilong, et al.
Publicado: (2021)

Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double‐Blind, Dose Escalation, Placebo‐ and Positive‐Controlled, Phase 1/2 Trial
por: Xu, Xiaowei, et al.
Publicado: (2021)

Tranexamic Acid for Blood Loss after Transforaminal Posterior Lumbar Interbody Fusion Surgery: A Double-Blind, Placebo-Controlled, Randomized Study
por: He, Bin, et al.
Publicado: (2020)

Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial
por: Feng, Guang-Wei, et al.
Publicado: (2023)

OA01.14. Efficacy of gorakhmundi In obesity: A single-blind placebo-controlled study
por: Wagh, Madhuri Hemant
Publicado: (2012)

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study
por: Li, Yinjuan, et al.
Publicado: (2021)

The Efficacy and Safety of a Herbal Toothpaste in Reducing Gingivitis: A Double-Blind, Randomized, Placebo-Controlled, Parallel Allocation Clinical Trial
por: He, Jinfeng, et al.
Publicado: (2019)

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
por: Hannawi, Suad, et al.
Publicado: (2022)

Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Liu, Guosong, et al.
Publicado: (2015)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
por: Chen, Gui-Ling, et al.
Publicado: (2022)

Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial
por: Abarca, Katia, et al.
Publicado: (2020)

Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
por: Tkachuk, Artem P., et al.
Publicado: (2020)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
por: Nadeem, Aroosa Younis, et al.
Publicado: (2022)

Kuntai capsules improve glucolipid metabolism in patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial
por: Liang, Ruining, et al.
Publicado: (2019)

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study
por: Yu, Hui Jing, et al.
Publicado: (2023)

Effects of Danhong injection on cardiac function and blood lipid in patients with angina pectoris of coronary heart disease: A protocol for randomized, double-blind, placebo-controlled clinical trial
por: Liang, Jian, et al.
Publicado: (2021)

Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
por: Han, Yuling, et al.
Publicado: (2022)

Randomized, Double-Blind, and Placebo-Controlled Trial of Clenbuterol in Denervated Muscle Atrophy
por: Jiang, Guang-Liang, et al.
Publicado: (2011)

A new recombined porcine reproductive and respiratory syndrome virus virulent strain in China
por: Dong, Jian-guo, et al.
Publicado: (2018)

OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial
por: Salmon-Céron, D, et al.
Publicado: (2009)

Expression and Immunogenicity of Two Recombinant Fusion Proteins Comprising Foot-and-Mouth Disease Virus Structural Protein VP1 and DC-SIGN-Binding Glycoproteins
por: Liu, Xinsheng, et al.
Publicado: (2017)

The necessity of pretreatment with 0.1% pranoprofen for femtosecond-assisted cataract surgery: A single-center, randomized controlled trial
por: Geng, Zhao, et al.
Publicado: (2023)

Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
por: Deng, Haiping, et al.
Publicado: (2020)

Immunogenicity Analysis of the Recombinant Plasmodium falciparum Surface-Related Antigen in Mice
por: Yu, Jia-Li, et al.
Publicado: (2022)

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy
por: de Jong, Wesley, et al.
Publicado: (2019)

Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice
por: Zhao, Hui, et al.
Publicado: (2015)

Addition of Celebrex and Pregabalin to Ropivacaine for Posterior Spinal Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial
por: Zhang, Ye, et al.
Publicado: (2021)

Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer
por: Wang, De‐shen, et al.
Publicado: (2019)

Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy
por: de Jong, Wesley, et al.
Publicado: (2019)

Construction and immunogenicity of a recombinant fowlpox vaccine coexpressing S1 glycoprotein of infectious bronchitis virus and chicken IL-18
por: Chen, Hong-Ying, et al.
Publicado: (2010)

Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial
por: Chen, Mu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_odignnrio9q6po837ln7tbjrkj